FINWIRES · TerminalLIVE
FINWIRES

Boston Scientific 2026 Guidance Cut 'Prudent,' Q2 Trough Expected, RBC Says

By

Boston Scientific (BSX) posted Q1 sales and earnings per share beats alongside a "prudent" guidance cut, with Q2 expected to be the trough quarter, RBC Capital Markets said in a note Wednesday.

The analysts said management lowered 2026 organic growth outlook to 6.5% to 8% due to "unanticipated headwinds" and "changing business patterns," though many investors already expected a reset, including those who believed the company could make the numbers to reset the base.

The analysts called Q1 a "clearing event," with Boston Scientific reporting Electrophysiology growing 21.7% year-over-year on an organic basis versus 18.5% consensus, while Watchman grew 18.8% versus 21.5% consensus, broadly in line with expectations.

"Looking ahead, we view Q2 as a trough quarter (guided 5% to 7%) with improving growth thereafter aided by new products, improvement in base businesses, and Watchman growth in low double digits. We would be buyers at current valuations," the analysts said.

RBC reiterated its outperform rating on Boston Scientific and adjusted its price target to $100 from $105.

Price: $65.76, Change: $+0.89, Percent Change: +1.37%

Related Articles

Wire

New Hope Completes AU$300 Million Convertible Notes Offering

New Hope (ASX:NHC) completed a AU$300 million issuance of 2.625% senior unsecured convertible notes due 2032 and the concurrent repurchase of AU$293.3 million of its existing 2029 convertible notes, according to a Thursday filing with the Australian bourse.The new notes are expected to be listed on the Singapore Exchange Securities Trading on or around Thursday, per the filing.The repurchased 2029 notes, which account for around 98% of the outstanding notes, will be cancelled under their terms, the filing said. The company also plans to redeem the remaining AU$6.7 million of notes at par plus accrued interest prior to maturity.

ASX:NHC
Wire

Telix Pharmaceuticals Settles Issue of $600 Million Convertible Notes

Telix Pharmaceuticals (ASX:TLX) said it settled the issue of $600 million in 1.50% convertible notes due 2031, according to a Thursday Australian bourse filing.The convertible notes are expected to be listed on the Official List of the Singapore Exchange Securities Trading on Thursday.In the same filing, the company said that the repurchase of around AU$637 million in principal of the AU$650 million worth of 2.375% convertible bonds due 2029 is "substantially complete."After the repurchase, given that less than 15% in aggregate principal amount of the existing bonds will remain outstanding, Telix said it plans to exercise its right to repurchase and cancel all of the remaining existing bonds at their principal amount.

ASX:TLX
Wire

Century Communities Q1 Adjusted Earnings, Revenue Fall

Century Communities (CCS) reported Q1 adjusted earnings late Wednesday of $0.88 per diluted share, down from $1.39 a year earlier.Three analysts polled by FactSet expected $0.59.Revenue for the three months ended March 31 fell to $789.7 million from $903.2 million a year earlier.Four analysts surveyed by FactSet expected $807.7 million.

$CCS